| LGCSX | RWIAX | LGCSX / RWIAX | |
| Total Expense Ratio | 0.90 | 1.51 | 60% |
| Annual Report Gross Expense Ratio | 1.04 | 1.51 | 69% |
| Fund Existence | 9 years | 24 years | - |
| Gain YTD | 8.840 | 15.218 | 58% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 250 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 399M | 160B | 0% |
| Annual Yield % from dividends | 0.46 | 0.73 | 62% |
| Returns for 1 year | 21.45 | 20.85 | 103% |
| Returns for 3 years | 73.47 | 49.70 | 148% |
| Returns for 5 years | 40.41 | 31.19 | 130% |
| Returns for 10 years | N/A | 102.34 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| CSHZX | 13.70 | 0.15 | +1.11% |
| NYLI Cushing® MLP Premier Class I | |||
| FSMAX | 116.33 | N/A | N/A |
| Fidelity Extended Market Index | |||
| ACIZX | 66.86 | N/A | N/A |
| Alger Capital Appreciation Instl Z-2 | |||
| BIPIX | 80.88 | N/A | N/A |
| ProFunds Biotechnology UltraSector Inv | |||
| TASVX | 22.54 | N/A | N/A |
| PGIM Quant Solutions Small-Cap Val Z | |||